EARLY DETECTION OF GENITAL HUMAN PAPILLOMAVIRUSINFECTION IN REPRODUCTIVE-AGED WOMEN: INTEGRATIONOF SELF-SAMPLING AND MOLECULAR BIOMARKER-BASEDTRIAGE

Rakhmanova Nozima Kakhramon qizi

Authors

Rakhmanova Nozima Kakhramon qizi

Keywords:

High-risk human papillomavirus, Cervical cancer screening, Reproductive-aged women, Molecular triage, DNA methylation biomarkers

Abstract

Persistent infection with high-risk human papillomavirus (hrHPV) remains the principal etiological factor in cervical carcinogenesis, disproportionately affecting women of reproductive age. Despite the global transition from
cytology-based screening to primary HPV testing, challenges remain in distinguishing transient infections from transforming lesions requiring clinical intervention.

References

1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6

2. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol.

1999;189(1):12–19.https://doi.org/10.1002/(SICI)1096-9896(199909)189:1

3. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer:follow-up of European randomised

controlledtrials.Lancet.2014;383(9916):524-532.https://doi.org/10.1016/S0140-

6736(13)62218-7

4. Schiffman M, Wentzensen N, Perkins RB, Guido RS. An introduction to the 2019 ASCCP RiskBased Management Consensus Guidelines. J Low Genit TractDis.2020;24(2):87–89.https://doi.org/10.1097/LGT.0000000000000528

5. Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823. https://doi.org/10.1136/bmj.k4823

6. Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 Dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst.

2015;107(12):djv257.https://doi.org/10.1093/jnci/djv257

7. De Strooper LMA, Verhoef VMJ, Berkhof J, et al. Validation of the AM19A4/mir124-2 DNA methylation test for cervical cancer screening.

Int J Cancer. 2016;138(11):2743–2752.https://doi.org/10.1002/ijc.29963

8. Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation analysis of FAM19A4 and CADM1 in hrHPV-positive women. Br J Cancer. 2014;111(6):1091–1098. https://doi.org/10.1038/bjc.2014.411

9. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva:

WHO; 2021. https://www.who.int/publications/i/item/9789240030824

10. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353(20):2101–2104https://doi.org/10.1056/NEJMp058171